- Home
- ACRV vs ANEB Comparison
ACRV vs ANEB Comparison
Compare ACRV & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- ANEB
- Stock Information
- Founded
- ACRV 2018
- ANEB 2020
- Country
- ACRV United States
- ANEB United States
- Employees
- ACRV N/A
- ANEB N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- ACRV Health Care
- ANEB Health Care
- Exchange
- ACRV Nasdaq
- ANEB Nasdaq
- Market Cap
- ACRV 42.5M
- ANEB 36.7M
- IPO Year
- ACRV 2022
- ANEB 2021
- Fundamental
- Price
- ACRV $1.81
- ANEB $1.01
- Analyst Decision
- ACRV Strong Buy
- ANEB Buy
- Analyst Count
- ACRV 6
- ANEB 1
- Target Price
- ACRV $21.80
- ANEB $8.00
- AVG Volume (30 Days)
- ACRV 412.6K
- ANEB 34.3K
- Earning Date
- ACRV 05-13-2025
- ANEB 05-14-2025
- Dividend Yield
- ACRV N/A
- ANEB N/A
- EPS Growth
- ACRV N/A
- ANEB N/A
- EPS
- ACRV N/A
- ANEB N/A
- Revenue
- ACRV N/A
- ANEB N/A
- Revenue This Year
- ACRV N/A
- ANEB N/A
- Revenue Next Year
- ACRV N/A
- ANEB N/A
- P/E Ratio
- ACRV N/A
- ANEB N/A
- Revenue Growth
- ACRV N/A
- ANEB N/A
- 52 Week Low
- ACRV $1.30
- ANEB $0.80
- 52 Week High
- ACRV $11.51
- ANEB $3.30
- Technical
- Relative Strength Index (RSI)
- ACRV 34.69
- ANEB 39.13
- Support Level
- ACRV $1.30
- ANEB $0.94
- Resistance Level
- ACRV $2.19
- ANEB $1.12
- Average True Range (ATR)
- ACRV 0.32
- ANEB 0.13
- MACD
- ACRV 0.10
- ANEB -0.01
- Stochastic Oscillator
- ACRV 51.00
- ANEB 22.00
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.